EU Deal...IMO..this is what Avnr wants...and will get
50M up front. 20% of revenues. This will cover both PBA and ALL future uses of the drug. For each subsequent use partner will pay a one time milestone payment of 20~30M. Partner and Avnr will live happily ever after for 22 years.
Scenario # 2. A big pharma makes an offer for the entire company...6 to 8 to 10/share. A key reason being they could simply make this company profitable today by eliminating all duplication.
You're out of your mind. The partner will pay MAYBE $4-5million up front (if at all), and royalties will be in the 12-15% range. Milestones for subsequent uses? That's not a milestone, idiot. And there won't be any such thing in any event.
There will also be no buyout, not a chance. Not until sales are at least triple what they are now. A buyout right now wouldn't fetch $4, yet alone the numbers you keep spouting.
You have no concept of business, especially the pharma business. You're just a full of himself troll who loves to hear the sound of his own voice.